Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03715829 · ClinicalTrials.gov registry record · Phase 2
A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 366
- Enrollment target
NCT03715829 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 366 participants.
The verdict
NCT03715829, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 366 participants
- Enrollment target
Study Summary
This is a Phase 2b, randomized, double blind, parallel group, multicenter study with an extension period. The study will have a maximum duration of approximately 60 weeks. This includes an up to 4 weeks Screening Period, a 24 week dose ranging period, an up to 24 week extension period and a 8 week Follow up Period.
Interventions
- DRUG PF-06651600
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 366 participants |
| Start Date | 2018-11-26 |
| Est. Completion | 2021-02-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03715829
The ClinicalTrials.gov registry entry for NCT03715829 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 366 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-06651600 is the first listed.
NCT03715829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03715829 about?
NCT03715829 is a clinical study titled "A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects". This is a Phase 2b, randomized, double blind, parallel group, multicenter study with an extension period. The study will have a maximum duration of approximately 60 weeks. This includes an up to 4 weeks Screening Period, a 24 week dose ranging period, an up to 24 week extension period and a 8 week F...
What is the current status of trial NCT03715829?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 366 participants. The study started on 2018-11-26. Estimated completion is 2021-02-05.
What interventions are being tested in trial NCT03715829?
The interventions under investigation include: PF-06651600 (DRUG).
Who is sponsoring clinical trial NCT03715829?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.